Serologic Responses to ACYW135 Polysaccharide Meningococcal Vaccine in Saudi Children under 5 Years of Age
Open Access
- 1 May 2005
- journal article
- clinical trial
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 73 (5), 2932-2939
- https://doi.org/10.1128/iai.73.5.2932-2939.2005
Abstract
An immunization campaign with meningococcal ACYW135 polysaccharide vaccine was conducted in 2003 by the Saudi Arabian Ministry of Health and included a study to evaluate the immune responses in children under 5 years of age in the Al Qassim region of Saudi Arabia. Children who were ≥24 months old were given one dose of tetravalent polysaccharide vaccine, while younger children were given two doses with an interval of 2 to 3 months. Blood samples were collected prevaccination and 1 month after the second dose for children younger than 24 months old and 1 month after the single dose for older children. Serogroup-specific antibody responses were determined by serum bactericidal antibody (SBA) assays and a tetraplex immunoglobulin G (IgG) bead assay. Significant increases in the proportions of individuals who were ≥24 months old with SBA titers of ≥8 were observed pre- to postvaccination for all serogroups. Age-dependent increases in the percentage of individuals with SBA titers of ≥8 1 month postvaccination were observed for each serogroup. Age-dependent increases in postvaccination IgG levels were observed for serogroup A (menA), serogroup W135 (menW), and serogroup Y (menY) but not for serogroup C (menC). Two doses of tetravalent polysaccharide vaccine in individuals who were ≤18 months old were poorly immunogenic for menC, menW, and menY. However, for menA, 42% of the children who were 18 months old were putatively protected with SBA titers of ≥8. A high percentage of subjects who were ≥2 years of age were putatively protected for menA; a similar level was observed for menY for children who were 4 years of age but not for younger children. However, for menC and menW poor levels of putative protection were still evident at 4 years of age.Keywords
This publication has 26 references indexed in Scilit:
- Development and Evaluation of a Tetraplex Flow Cytometric Assay for Quantitation of Serum Antibodies to Neisseria meningitidis Serogroups A, C, Y, and W-135Clinical and Vaccine Immunology, 2004
- Assignment ofNeisseria meningitidisSerogroups A, C, W135, and Y Anticapsular Total Immunoglobulin G (IgG), IgG1, and IgG2 Concentrations to Reference SeraClinical and Vaccine Immunology, 2004
- Immunologic Hyporesponsiveness to Serogroup C but Not Serogroup A following Repeated Meningococcal A/C Polysaccharide Vaccination in Saudi ArabiaClinical and Vaccine Immunology, 2004
- Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in EnglandClinical and Vaccine Immunology, 2003
- Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccineFEMS Immunology & Medical Microbiology, 2000
- Reactogenicity and Immunogenicity of a Quadrivalent Combined Meningococcal Polysaccharide Vaccine in ChildrenThe Journal of Infectious Diseases, 1986
- Tetravalent (A, C, Y, W 135) meningococcal vaccine in children: Immunogenicity and safetyVaccine, 1985
- Clinical Efficacy of Meningococcus Group A Capsular Polysaccharide Vaccine in Children Three Months to Five Years of AgeNew England Journal of Medicine, 1977
- Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants.Journal of Clinical Investigation, 1975
- EFFECT OF GROUP-A MENINGOCOCCAL VACCINE IN ARMY RECRUITS IN FINLANDThe Lancet, 1975